Literature DB >> 7526796

The interferons: a biological system with therapeutic potential in viral infections.

S Baron1, F Dianzani.   

Abstract

Successful medical use of interferon for chronic viral infections is increasingly dependent on understanding the biologic and molecular mechanisms of the interferon system. Interferon (IFN) is one of the body's natural defenses. Production of IFN is a defensive response to foreign components of microbes, tumors and antigens. This IFN response begins with the production of the IFN proteins (alpha, beta and gamma) which then induce antiviral, antimicrobial, antitumor, and immunomodulatory actions. Thus, the initial production or administration of IFN(s) does not protect directly but instead reacts with specific receptors on cell surfaces to activate cytoplasmic transduction signals that then enter the nucleus to stimulate cellular genes encoding a number of effector proteins which lead to the defensive actions. The known molecular, humoral and cellular mechanisms by which these effector proteins exert their antiviral activities are presented. In addition, the pathogenesis of chronic infections is overviewed in the context of the interferon defenses.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7526796     DOI: 10.1016/0166-3542(94)90058-2

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  15 in total

1.  A phase 2 study of pegylated interferon α-2b (PEG-Intron(®)) in children with diffuse intrinsic pontine glioma.

Authors:  Katherine Warren; Robyn Bent; Pamela L Wolters; Alisa Prager; Ryan Hanson; Roger Packer; Joanna Shih; Kevin Camphausen
Journal:  Cancer       Date:  2011-11-15       Impact factor: 6.860

2.  Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-α on pancreatic cancer cells.

Authors:  Shuichi Iwahashi; Mitsuo Shimada; Tohru Utsunomiya; Yuji Morine; Satoru Imura; Tetsuya Ikemoto; Hiroki Mori; Jun Hanaoka; Koji Sugimoto; Yu Saito
Journal:  Int J Clin Oncol       Date:  2011-05-10       Impact factor: 3.402

3.  Expression of naked DNA in human, pig, and mouse skin.

Authors:  U R Hengge; P S Walker; J C Vogel
Journal:  J Clin Invest       Date:  1996-06-15       Impact factor: 14.808

4.  Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferon-alpha.

Authors:  S Ozawa; H Shinohara; H O Kanayama ; C J Bruns; C D Bucana; L M Ellis; D W Davis; I J Fidler
Journal:  Neoplasia       Date:  2001 Mar-Apr       Impact factor: 5.715

5.  STAT1 pathway is involved in activation of caprine arthritis-encephalitis virus long terminal repeat in monocytes.

Authors:  T Sepp; S E Tong-Starksen
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

6.  Inhibitory effect of interferon-alpha-2b on expression of cyclooxygenase-2 and vascular endothelial growth factor in human hepatocellular carcinoma inoculated in nude mice.

Authors:  Bin Cao; Xiao-Ping Chen; Peng Zhu; Lei Ding; Jian Guan; Zuo-Liang Shi
Journal:  World J Gastroenterol       Date:  2008-11-28       Impact factor: 5.742

7.  MiR-139 Induces an Interferon-β Response in Prostate Cancer Cells by Binding to RIG-1.

Authors:  Robert K Nam; Tania Benatar; Yutaka Amemiya; Arun Seth
Journal:  Cancer Genomics Proteomics       Date:  2021 May-Jun       Impact factor: 4.069

8.  Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma.

Authors:  T Noda; H Nagano; I Takemasa; S Yoshioka; M Murakami; H Wada; S Kobayashi; S Marubashi; Y Takeda; K Dono; K Umeshita; N Matsuura; K Matsubara; Y Doki; M Mori; M Monden
Journal:  Br J Cancer       Date:  2009-04-28       Impact factor: 7.640

9.  Combination of interferon-alpha and 5-fluorouracil inhibits endothelial cell growth directly and by regulation of angiogenic factors released by tumor cells.

Authors:  Hiroshi Wada; Hiroaki Nagano; Hirofumi Yamamoto; Takehiro Noda; Masahiro Murakami; Shogo Kobayashi; Shigeru Marubashi; Hidetoshi Eguchi; Yutaka Takeda; Masahiro Tanemura; Koji Umeshita; Yuichiro Doki; Masaki Mori
Journal:  BMC Cancer       Date:  2009-10-12       Impact factor: 4.430

10.  Influence of the presence of HCV-RNA in peripheral blood mononuclear cells on the clinical course of chronic hepatitis C in children.

Authors:  Arleta Kowala-Piaskowska; Iwona Mozer-Lisewska; Magdalena Figlerowicz; Wojciech Słuzewski
Journal:  Eur J Epidemiol       Date:  2007-05-05       Impact factor: 12.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.